Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cance...( EMERYVILLE Calif. April 15 /- Bio...)

EMERYVILLE, Calif., April 15 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq: BNVI) will present findings on the mechanism of action of two of its anti-cancer agents BN107 and BN108 at the American Association of Cancer Research (AACR) being held at the San Diego Convention Center in San Diego, CA, April 12 - 16, 2008.

Bionovo's poster presentation will describe the pathway for cancer cell apoptosis (cell death) induced by BN107 and BN108. As explained by Dr. Emma Shtivelman, Director of Cancer Research at Bionovo, the ability of BN107 to induce death cancer cell death is distinct from that of BN108. BN107 induces apoptosis through the mitochondrial pathway. BN107 induces death only in estrogen receptor negative breast cancer cells. BN108 induces cancer cell death by rapid inactivation of both AKT and mTOR pathways in breast cancer cells, but not in normal cells.

"BN107 and BN108 mechanisms of action and unique selective properties are a result of some of the biological differences between cancer cells and normal cells as well as cancer cells' uniquely acquired functions," said Dr. Isaac Cohen, President and CEO of Bionovo. "We believe both drugs will result in better tolerability and better toxicity profile than conventional chemotherapy due to better target selectivity. Oral administration will provide availability for chronic treatment and will mark these new targeted compounds as promising investigational drugs."

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and
'/>"/>